Doral, FL, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, medical device, research and development, has signed an agreement with Axcelon Biopolymers Corp for the exclusive distribution of their Nanoderm™ Biopolymer products in Morocco and Djibouti, which was hinted in the beginning of August.
NanodermTM is a unique wound care product, which is used by hospitals, clinics, and the general public for a variety of wound treatments, including burns, scratches, and more serious wounds like diabetic foot ulcers. It is also excellent for soldiers during missions. Unlike regular bandages, Nanoderm™ is applied only once over most wounds, where it remains for the duration of the healing process. It provides a barrier to infections, while allowing air to pass through. This promotes healing and reduces pain. For these reasons, active consumers and travelers enjoy the flexibility of the treatment.
As the exclusive distributor in the two mentioned countries, ETST will be marketing two medical devices at the same time; the MSN-2 medical device for STI testing and the Nanoderm™ product.
“We are very proud to launch Nanoderm™ products in countries where we are planning to introduce our innovative MSN-2 medical device through Earth Science Pharmaceutical, Inc.,” said CEO & CSO, Dr. Michel Aubé, “This will allow for the development of cost-sharing promotion plans. Axcelon products are already certified for sale among Canada and many other countries. We are working to expand the distribution exclusivities mostly in already industrialized countries”
View Nanoderm’s website for more information on the product.
Advances in MSN-2 Project, New Canadian filial created
ETST has officially created a new filial company, Canna Inno Laboratories, Inc., which will be instrumental in the research and testing needed to bring new and innovative nutraceutical products to market. Many of the partners who are involved in the final testing and process development for the ETST nutraceutical products already in the pipeline are located in Québec, Canada. As a Canadian company, the new subsidiary will be better placed to work with local governments in Québec to ensure that the work meets standards as well as receiving grants for further studies.
In other news, ETST has found a clinic in Québec to conduct pre-launch testing of the MSN-2. The name of the clinic specialized in meeting the needs of at-risk youth and youth in difficulty will be announced soon. As STI are a significant problem for this demographic, the clinic is well-positioned to conduct testing of the MSN-2. In a short period of time we will help many young women in difficulty escape the serious consequences of an untreated STI.
Nickolas S. Tabraue, ETST’s President, Director, & COO concluded with, “Earth Science Tech is lining up to truly be a leading biotech company as we partner up with innovative companies and diversify solutions to help with many common conditions. We have many exciting announcements and updates on our patents, KannaBidioiD subsidiary, distribution, education strategy, and expansion I look forward on sharing very soon.”
About Earth Science Tech, Inc. (ETST): Earth Science Tech has the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the world's best supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research performed alongside the University of Central Oklahoma and DV Biologics laboratory, prove we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. To learn more please visit: www.earthsciencetech.com
View ETST's accomplishments and reports on its High-Grade CBD Hemp Oil: (here)
About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.Earthsciencepharmaceutical.com
About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.Cannabisthera.com
About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by it's unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.
Website coming soon: www.kannabidioidinc.com
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements and products have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. The FDA has not evaluated the validity or truthfulness of these claims; therefore, we encourage you to review published researches relating to the benefits and properties of CBD hemp oils and other CBD products.
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.